Interdisciplinary Life Science - PULSe Great research is a matter of choice

Marxa Figueiredo

Marxa Figueiredo Profile Picture

Assistant Professor
Purdue University College of Veterinary Medicine
625 Harrison Street
West Lafayette, IN 47907


Contact Info:

mlfiguei@purdue.edu


Training Group(s):
Immunology and Infectious Diseases
Molecular Signaling and Cancer Biology


Current Research Interests:

Our laboratory aims to understand the interactions between the skeletal and immune systems with the goal to develop novel therapeutic applications. We focus on integrating biological mechanisms with development of strategies that can leverage the immune system to simultaneously promote restoration of bone and alter immune responses to control inflammation or cell viability. Our therapeutic modalities build on multifunctional osteo-immune cytokines, which can be targeted to bone or inflammatory cells in order to exert regenerative effects.

We develop several gene delivery and stem cell delivery systems for cytokine-based gene therapy. We utilize sonoporation gene delivery (sonodelivery) and adipose-derived mesenchymal stem cells as vehicles. Our lab has evolved to pursue three project directions.

Project 1 is designed to disrupt immune: bone malignant interactions using multifunctional cytokine sonodelivery. We develop more effective therapies for inflammatory bone loss (arthritis) as well as metastatic prostate cancer using intramuscular sonodelivery of targeted cytokines including IL-27 and OP-1. We utilize modern optical and other modalities of noninvasive molecular imaging to detect therapy delivery and efficacy in vivo. Project 2 examines the biology and potential of ASC for tissue regeneration, including bone repair and for halting tumor promotion. Conversely, for understanding how stroma can promote tumor growth, we examine the role of ASC in mediating the effects of environmental toxicants. Project 3 develops small molecule mimics of Pigment Epithelial Growth Factor (PEDF), a potent antiangiogenic and pro-osteogenic molecule, with translational potential for bone regeneration and antitumor applications. We also utilize modern optical and other modalities of noninvasive molecular imaging to detect therapy delivery and efficacy in vivo.



Selected Publications:

Ellis, J, Falzon, M, Emrick, T, and Figueiredo, ML. Imaging cytokine targeting to the tumor/bone microenvironment in vivo. Human Gene Ther Clin Devel. 2014 In press.

Parelkar, S, Letteri, R, Chan-Seng , D, Zolochevska, O, Ellis, J, Figueiredo, ML, Emrick, T. Polymer-peptide delivery platforms: effect of oligopeptide orientation on polymer-based DNA delivery. Biomacromolecules. 2014 Apr 14;15(4):1328-36.

Zolochevska, O, Shearer, J., Ellis, J, Fokina, V, Shah, F, Gimble, J, and Figueiredo, ML. Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells. Cytotherapy. 2014 Mar;16(3):346-56.(Cover of Mar 2014 issue)

Zolochevska, O, Parelkar, R, Emrick, T., Patrikeev, I, Wei, J, Motamedi, M., and Figueiredo. ML. A novel role for Interleukin-27 gene therapy in modifying in vivo malignant interactions between prostate tumor and bone. Hum Gene Ther. 2013 Dec;24(12):970-81. (Cover of Dec 2013 issue)

Zolochevska, O, Diaz-Quiñones, A.O., Ellis, J., and Figueiredo, ML. Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro. J Cell Physiol. 2013 May;228(5):1127-36.

Zolochevska, O and Figueiredo, ML. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function. Prostate. 2009 Oct 1;69(14):1586-97.

Zolochevska, O, Yu, G, Gimble, J, and Figueiredo, ML. PEDF and MDA-7 cytokine gene therapies delivered by adipose-derived mesenchymal stem cells are effective in reducing prostate cancer cell growth. Stem Cells Dev. 2012 May 1;21(7):1112-23.

Zolochevska, O and Figueiredo, ML. Sonoporation delivery of Interleukin 27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther. 2011 Dec;22(12):1537-50

Zolochevska, O and Figueiredo, ML. Cell cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells. Prostate. 2011 Mar 1;71(4):353-67.

Zolochevska, O and Figueiredo, ML. Novel growth inhibition mechanism by cell cycle regulator cdk2ap1 involves modulation of anti-angiogenesis. Microvasc Res. 2010 Dec;80(3):324-31.

  • Faculty Profile

Ernest C. Young Hall, Room 170 | 155  S. Grant Street, West Lafayette, IN 47907-2114 | 765-494-2600

© 2017 Purdue University | An equal access/equal opportunity university | Copyright Complaints | Maintained by The Purdue University Graduate School

If you have trouble accessing this page because of a disability, please contact The Purdue University Graduate School.